Business
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Highlights: 100% of Patients in Cohort 1 Achieve Primary Efficacy EndpointNo Treatment-Related Adverse Effects ObservedPreserves Cancer Treatment Efficacy
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Highlights:\n100% of Patients in Cohort 1 Achieve Primary Efficacy EndpointNo Treatment-Related Adverse Effects ObservedPreserves Cancer Treatment Efficacy with Zero Dose ReductionsNEW YORK, Jan. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients.\n\n \n \n \n \n \n \n\n \nExceptional Patient Outcomes:\nData from the open-label portion of the CLEER-001 trial demonstrated remarkable success:\n100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.66% of patients reported reduced pain and itching scores, further enhancing quality of life.Crucially, all patients maintained their full EGFRi dosage, preserving the cancer treatment's full therapeutic effect—a notable improvement compared to past reports showing widespread dose reductions or treatment halts due to skin-related side effects.\nA Groundbreaking Approach:\nThe trial uses the proprietary Acneiform Rash Investigator Global Assessment Scale (ARIGA), developed in collaboration with onco-dermatology experts. The innovative scale ensures precise measurement and assessment of skin toxicity improvements.\nRobb Knie, CEO of Hoth Therapeutics, remarked, \"These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments. Our data highlight HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area.\"\nA Strong Safety Profile:\nNo treatment-related adverse effects have been reported, reaffirming HT-001's excellent tolerability.\nLooking Ahead:\n\"These interim findings align with a recent case report of rapid resolution of EGFRi-induced skin conditions using HT-001,\" added Knie. \"As the study progresses, we anticipate further validating these results and are excited about the potential impact HT-001 could have on patient outcomes.\"\nHoth Therapeutics is committed to advancing groundbreaking treatments and improving pa...